CA2666609A1 - Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases - Google Patents

Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases Download PDF

Info

Publication number
CA2666609A1
CA2666609A1 CA002666609A CA2666609A CA2666609A1 CA 2666609 A1 CA2666609 A1 CA 2666609A1 CA 002666609 A CA002666609 A CA 002666609A CA 2666609 A CA2666609 A CA 2666609A CA 2666609 A1 CA2666609 A1 CA 2666609A1
Authority
CA
Canada
Prior art keywords
thymosin alpha
treatment
disease
ibd
autoimmune diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002666609A
Other languages
English (en)
French (fr)
Inventor
Luigina Romani
Francesco Bistoni
Enrico Garaci
Guido Rasi
Paola Sinibaldi Vallebona
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2666609A1 publication Critical patent/CA2666609A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA002666609A 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases Abandoned CA2666609A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM2006A000584 2006-10-27
IT000584A ITRM20060584A1 (it) 2006-10-27 2006-10-27 Uso della timosina alfa 1 la preparazione di un medicamento per la prevenzione e la cura delle malattie autoimmuni
PCT/IT2007/000677 WO2008050363A2 (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
CA2666609A1 true CA2666609A1 (en) 2008-05-02

Family

ID=39322489

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002666609A Abandoned CA2666609A1 (en) 2006-10-27 2007-09-27 Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases

Country Status (13)

Country Link
US (1) US20100004174A1 (cg-RX-API-DMAC10.html)
EP (1) EP2086569A2 (cg-RX-API-DMAC10.html)
JP (1) JP2010507650A (cg-RX-API-DMAC10.html)
KR (1) KR20090096688A (cg-RX-API-DMAC10.html)
CN (1) CN101534853A (cg-RX-API-DMAC10.html)
AU (1) AU2007310416A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0718010A2 (cg-RX-API-DMAC10.html)
CA (1) CA2666609A1 (cg-RX-API-DMAC10.html)
EA (1) EA200900602A1 (cg-RX-API-DMAC10.html)
IL (1) IL198291A0 (cg-RX-API-DMAC10.html)
IT (1) ITRM20060584A1 (cg-RX-API-DMAC10.html)
MX (1) MX2009004196A (cg-RX-API-DMAC10.html)
WO (1) WO2008050363A2 (cg-RX-API-DMAC10.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100248272A1 (en) * 2009-03-31 2010-09-30 Cornell University Method for identifying Smk box riboswitch modulating compounds
WO2025078961A1 (en) * 2023-10-13 2025-04-17 Gufic Biosciences Limited Composition and method for treatment of endometriosis

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5852225A (ja) * 1981-09-22 1983-03-28 Mitsui Pharmaceut Inc 脱髄疾患治療剤
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US5468729A (en) * 1993-10-26 1995-11-21 Alpha 1 Biomedicals Method for treatment of autoimmune hepatitis
US5888980A (en) * 1994-06-30 1999-03-30 Bio-Logic Research And Development Corporation Compositions for enhancing immune function
WO1998018491A1 (en) * 1996-10-28 1998-05-07 BURGSTINER, Jacqueline, Cook Methods and compositions for dietary supplementation
CN1198950A (zh) * 1998-04-24 1998-11-18 崔泊 一种结肠炎新药的制备
CN1628796A (zh) * 2004-08-20 2005-06-22 康合堂 一种治疗溃疡性结肠炎的药物

Also Published As

Publication number Publication date
EP2086569A2 (en) 2009-08-12
WO2008050363A2 (en) 2008-05-02
MX2009004196A (es) 2009-06-30
JP2010507650A (ja) 2010-03-11
BRPI0718010A2 (pt) 2013-11-19
US20100004174A1 (en) 2010-01-07
WO2008050363A3 (en) 2008-06-26
ITRM20060584A1 (it) 2008-04-28
CN101534853A (zh) 2009-09-16
KR20090096688A (ko) 2009-09-14
IL198291A0 (en) 2011-08-01
WO2008050363A8 (en) 2009-06-04
EA200900602A1 (ru) 2009-10-30
AU2007310416A1 (en) 2008-05-02

Similar Documents

Publication Publication Date Title
Ridge et al. Suppression of experimental allergic encephalomyelitis by mitoxantrone
EP2442832B1 (en) Compositions and methods for treatment of multiple sclerosis
Mori et al. Scleroderma-like cutaneous syndromes
CN111542335A (zh) 炎症性肠病的治疗药
US8771689B2 (en) Alpha B-crystallin as a therapy for ischemia or inflammation
KR20130036217A (ko) 라퀴니모드를 이용한 루푸스 관절염의 치료
Lerner-Natoli et al. Sequential expression of surface antigens and transcription factor NFκB by hippocampal cells in excitotoxicity and experimental epilepsy
Kumar et al. Novel formulation approaches used for the management of osteoarthritis: a recent review
Zhou et al. Effects of RANKL on the proliferation and apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis through regulating the NF-κB signaling pathway.
Karataş et al. Mango ginger (curcuma amada) inhibits collagen-induced arthritis by modulatinginflammatory cytokine levels in rats
US20100004174A1 (en) Use of thymosin alpha 1 for the preparation of a medicament for the prevention and treatment of autoimmune diseases
Willis et al. Intravenous immunoglobulin (IVIG) promotes brain repair and improves cognitive outcomes after traumatic brain injury in a FcγRIIB receptor-dependent manner
CN115052613B (zh) 包含肽或肽混合物作为活性成分的组合物及其医疗用途
Lavrnja et al. The effect of ribavirin on reactive astrogliosis in experimental autoimmune encephalomyelitis
JP2009533421A (ja) 炎症性疾患を治療するためのアセチルコリンエステラーゼに対するアンチセンスオリゴヌクレオチド
Pan et al. Angelicin alleviates sepsis-associated encephalopathy via inhibition of IKK2 and the NF-κB pathway
CN116019813B (zh) Vesatolimod在制备预防和/或治疗中枢神经系统疾病的药物中的应用
CN115052614A (zh) 包含肽或其混合物作为活性成分的用于预防或治疗白塞氏病和类风湿性关节炎的药物组合物
KR20080048542A (ko) 인간 유두종 바이러스에 저항하는 약제 제조를 위한노카르디아 루브라 세포벽 골격의 용도
JP5536037B2 (ja) 自己免疫疾患の治療における、ｐａｔノナペプチドの使用
CA2787727A1 (en) Transferrin for use in the treatment and/or prophylaxis of autoimmune diseases
JP5035582B2 (ja) 医薬組成物
JP2004533443A (ja) 治療的方法
CN120983423B (zh) 狭叶依瓦菊素在制备预防和/或治疗神经炎症的药物中的用途
JP4333901B2 (ja) リウマチ関節炎治療用プロディギオシン組成物

Legal Events

Date Code Title Description
FZDE Discontinued